Clinical Trials Logo

Filter by:
NCT ID: NCT04586010 Active, not recruiting - Clinical trials for Relapsing Multiple Sclerosis

A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS)

FENhance
Start date: March 17, 2021
Phase: Phase 3
Study type: Interventional

A study to evaluate the efficacy and safety of fenebrutinib on disability progression and relapse rate in adult participants with RMS. Eligible participants will be randomized 1:1 to either fenebrutinib or teriflunomide. Open-Label Extension (OLE) phase is contingent on a positive benefit-risk result in the Primary Analysis of the study.

NCT ID: NCT04363814 Active, not recruiting - COVID-19 Clinical Trials

Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection

Start date: June 10, 2020
Phase: Phase 3
Study type: Interventional

The purpose of the study is to confirm if BACTEK-R (MV130) provides clinical benefit in subject with mild pneumonia (CURB-65≤2) by COVID-19 admitted to the Hospital.

NCT ID: NCT04158258 Active, not recruiting - Breast Cancer Clinical Trials

A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America

Start date: February 21, 2020
Phase:
Study type: Observational

A Prospective, Multicenter, Non-Interventional Study of Primary Data Collection, Designed to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcomes in Patients with Breast Cancer in Latin America.

NCT ID: NCT04150068 Active, not recruiting - HIV-1-infection Clinical Trials

Study to Evaluate the Safety and Efficacy of Lenacapavir (GS-6207) in Combination With an Optimized Background Regimen (OBR) in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance

CAPELLA
Start date: November 21, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the antiviral activity of lenacapavir (formerly GS-6207) administered as an add-on to a failing regimen (functional monotherapy) in people living with HIV (PLWH) with multi-drug resistance (MDR).

NCT ID: NCT04029480 Active, not recruiting - Clinical trials for Type 2 Diabetes Mellitus

Ertugliflozin Type 2 Diabetes Mellitus (T2DM) Pediatric Study (MK-8835/PF-04971729) (MK-8835-059)

Start date: October 8, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the safety and efficacy of ertugliflozin (MK-8835) in pediatric participants with T2DM on metformin with/without insulin. The primary hypothesis of the study is that the addition of ertugliflozin reduces hemoglobin A1C (HbA1C) more than the addition of placebo after 24 weeks of treatment.

NCT ID: NCT03593590 Active, not recruiting - Multiple Sclerosis Clinical Trials

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis

MuSicalE
Start date: November 12, 2018
Phase:
Study type: Observational

This is a multicentre non-interventional study aimed at evaluating the real-world effectiveness and safety of ocrelizumab treatment in participants with relapsing multiple sclerosis (RMS) or primary progressive multiple sclerosis (PPMS), who have been prescribed ocrelizumab as per routine practice. This study will use a comprehensive combination of participant reported outcomes and conventional multiple sclerosis (MS) endpoints that measure clinical domains commonly affected by MS (e.g. fatigue, hand function, gait, cognition), and their impact on employment, activities of daily living, quality of life and healthcare resource utilization. The incidence, type, and pattern of serious adverse events (SAEs), and of adverse events (AEs) leading to treatment discontinuation will also be determined.

NCT ID: NCT03423979 Active, not recruiting - Clinical trials for Benign Prostatic Hyperplasia

Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter

EVEREST-I
Start date: December 19, 2017
Phase: Phase 2
Study type: Interventional

A prospective, non-randomized study. The subjects will be enrolled and treated with the Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The post-treatment follow-up visit can be up to 5 years. The objective of the study is to evaluate the safety and efficacy of the Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.

NCT ID: NCT03364946 Active, not recruiting - Hypoxia Clinical Trials

High Flow Therapy in ICUs Across Ibero America

T-Calfi
Start date: May 15, 2018
Phase:
Study type: Observational [Patient Registry]

The study aims to describe the use of Nasal High Flow (NHF) in the intensive care units of participating centers in Iberoamerica. It will describe the indications for the use, the clinical outcome of patients , and the therapeutic failure of NHF therapy in patients staying in an intensive care unit in the participant centers in Iberoamerica.

NCT ID: NCT02786186 Active, not recruiting - Psoriasis Clinical Trials

A Registry of Patients With Moderate to Severe Plaque Psoriasis

PURE
Start date: December 23, 2015
Phase:
Study type: Observational [Patient Registry]

The main purpose of the current study will be to provide real - world evidence regarding the safety and effectiveness of secukinumab in the management of patients with moderate to severe chronic plaque psoriasis.

NCT ID: NCT02769845 Active, not recruiting - Sickle Cell Anemia Clinical Trials

SACRED A Prospective Research Study to Reduce Stroke in Children With Sickle Cell Anemia

SACRED
Start date: March 16, 2016
Phase: N/A
Study type: Interventional

Prospective screening and treatment study for children with Sickle Cell Anemia and increased stroke risk living in the Dominican Republic.